4.5 Article

Combined Vhlh and Pten mutation causes genital tract cystadenoma and squamous metaplasia

Journal

MOLECULAR AND CELLULAR BIOLOGY
Volume 28, Issue 14, Pages 4536-4548

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.02132-07

Keywords

-

Ask authors/readers for more resources

Patients with von Hippel-Lindau (VHL) disease develop tumors in a range of tissues, but existing mouse models of Vhlh mutation have failed to reproduce these lesions. Epididymal cystadenomas arise frequently in VHL patients, but VHL mutation alone is believed to be insufficient for tumor formation, implying a requirement for cooperating mutations in epididymal pathogenesis. Here we show that epididymal cystadenomas from VHL patients frequently also lack expression of the PTEN tumor suppressor and display activation of phosphatidylinositol 3-kinase (PI3K) pathway signaling. Strikingly, while conditional inactivation of either Vhlh or Pten in epithelia of the mouse genital tract fails to produce a tumor phenotype, their combined deletion causes benign genital tract tumors with regions of squamous metaplasia and cystadenoma. The latter are histologically identical to lesions found in VHL patients. Importantly, these lesions are characterized by expansion of basal stem cells, high levels of expression and activity of HIF1 alpha and HIF2 alpha, and dysregulation of PI3K signaling. Our studies suggest a model for cooperative tumor suppression in which inactivation of PTEN facilitates epididymal cystadenoma genesis initiated by loss of VHL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pathology

METalterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features

Thomas Denize, Pierre Alexandre Just, Mathilde Sibony, Helene Blons, Marc Olivier Timsit, Tom Drossart, Deborah Jakubowicz, Chloe Broudin, Aurelien Morini, Thierry Molina, Yann Vano, Marie Auvray-Kuentz, Stephane Richard, Arnaud Mejean, Anne Paule Gimenez Roqueplo, Nelly Burnichon, Virginie Verkarre

Summary: Our study provides additional evidence that biphasic squamoid alveolar papillary RCC is a morphological variant of type 1 papillary renal RCC. Our data strongly suggest that MET represents a major oncogenic driver gene in BSA-PRCC, harboring a higher frequency of MET mutation that encourages further exploration of the benefits of anti-MET targeted therapies for aggressive BSA-PRCC.

MODERN PATHOLOGY (2021)

Article Oncology

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition

Antonella Catalano, Mojca Adlesic, Thorsten Kaltenbacher, Rhena F. U. Klar, Joachim Albers, Philipp Seidel, Laura P. Brandt, Tomas Hejhal, Philipp Busenhart, Niklas Roehner, Kyra Zodel, Kornelia Fritsch, Peter J. Wild, Justus Duyster, Ralph Fritsch, Tilman Brummer, Ian J. Frew

Summary: The study demonstrates that the combined use of MEK and ERK inhibitors can prevent the emergence of drug resistance, but may not be effective if cancer cells are resistant to single agents. Drug resistance involves complex rewiring of cellular kinase signaling networks, which are not overlapping between different cancer cell lines. The identification of new drug sensitivities in some resistant cells suggests potential additional therapeutic targets in oncogenic RAS-driven tumors.

CANCERS (2021)

Letter Clinical Neurology

A metastasis of a clear cell renal cell carcinoma in a spinal hemangioblastoma in the context of von Hippel-Lindau syndrome

Suzanne Tran, Samiya Abi Jaoude, Stephane Richard, Franck Bielle

CLINICAL NEUROPATHOLOGY (2021)

Article Oncology

Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma

Lucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cecile Vicier, Guillermo de Velasco, Aude Flechon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Paillerets, Marine Guillaud-Bataille, Pauline Gaignard, Jean-Yves Scoazec, Stephane Richard, Olivier Caron, Bernard Escudier, Laurence Albiges

Summary: This study is a retrospective analysis of FHdef RCC patients treated with systemic therapy, showing that antiangiogenics may be superior to ICB/mTOR inhibitors in this population.

EUROPEAN JOURNAL OF CANCER (2021)

Article Pathology

Clear cell and papillary renal cell carcinomas in hereditary papillary renal cell carcinoma (HPRCC) syndrome: a case report

Sophie Ferlicot, Pierre-Alexandre Just, Eva Comperat, Etienne Rouleau, Frederique Tissier, Christophe Vaessen, Stephane Richard

Summary: A rare autosomal dominant disease called Hereditary papillary renal cell carcinoma (HPRCC) is characterized by multiple and bilateral papillary type I renal cell carcinomas caused by activated mutations in the MET proto-oncogene. A case study of a 51-year-old man with HPRCC showed not only papillary tumors but also clear cell renal cell carcinomas. Immunohistochemistry and FISH testing revealed potential links between clear cell RCC and papillary RCC in the context of HPRCC syndrome.

DIAGNOSTIC PATHOLOGY (2021)

Article Genetics & Heredity

Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I

Molka Sebai, David Tulasne, Sandrine M. Caputo, Virginie Verkarre, Marie Fernandes, Celia Guerin, Fanny Reinhart, Severine Adams, Christine Maugard, Olivier Caron, Marine Guillaud-Bataille, Pascaline Berthet, Yves-Jean Bignon, Brigitte Bressac-de Paillerets, Nelly Burnichon, Jean Chiesa, Sophie Giraud, Sophie Lejeune, Jean-Marc Limacher, Antoine de Pauw, Dominique Stoppa-Lyonnet, Helene Zattara-Cannoni, Sophie Deveaux, Rosette Lidereau, Stephane Richard, Etienne Rouleau

Summary: Hereditary papillary renal cell carcinoma is a rare inherited renal cancer syndrome associated with activating germline pathogenic variants of the MET gene. A study on a large French patient series showed a correlation between MET pathogenic variants and characteristic presentation of PRCC1 tumors, highlighting the importance of broadening screening efforts.

HUMAN MUTATION (2022)

Article Medicine, General & Internal

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease

Eric Jonasch, Frede Donskov, Othon Iliopoulos, W. Kimryn Rathmell, Vivek K. Narayan, Benjamin L. Maughan, Stephane Oudard, Tobias Else, Jodi K. Maranchie, Sarah J. Welsh, Sanjay Thamake, Eric K. Park, Rodolfo F. Perini, W. Marston Linehan, Ramaprasad Srinivasan

Summary: The HIF-2α inhibitor belzutifan showed efficacy in patients with renal cell carcinoma associated with von Hippel-Lindau disease, with nearly half of the patients having an objective response to treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Oncology

Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors

Florine Adolphe, Sophie Ferlicot, Virginie Verkarre, Katia Posseme, Sophie Couve, Pauline Garnier, Nathalie Droin, Marc Deloger, Bastien Job, Sophie Giraud, Brigitte Bressac-de Paillerets, Betty Gardie, Stephane Richard, Flore Renaud, Sophie Gad

Summary: A frameshift mutation in the NBR1 gene was identified in a family with different histological renal tumors, suggesting NBR1 as a potential predisposing gene for RCC. Functional analysis indicated that the mutation affects autophagy and promotes increased proliferative capacity in renal cell lines. Further investigation is needed to confirm the characterization of NBR1 in renal carcinogenesis.

CANCER GENETICS (2021)

Article Oncology

Preimplantation genetic testing in patients with genetic susceptibility to cancer

Marie-Charlotte Villy, Nelly Frydman, Celine Moutou, Gaelle Thierry, Jade Raad, Chrystelle Colas, Julie Steffann, Julie Metras, Nathalie Chabbert-Buffet, Yann Parc, Stephane Richard, Patrick R. Benusiglio

Summary: Data on preimplantation genetic testing (PGT-M) in patients with genetic susceptibility to cancer are scarce. A retrospective multicenter study was conducted to collect data on PGT-M outcomes and raise awareness among cancer genetics professionals. The study showed satisfactory PGT-M outcomes in patients with cancer susceptibility syndromes, highlighting the need for systematic counseling and increased awareness of PGT-M among cancer genetics professionals.

FAMILIAL CANCER (2023)

Article Biochemistry & Molecular Biology

Minors at risk of von Hippel-Lindau disease: 10 years' experience of predictive genetic testing and follow-up adherence

Roseline Vibert, Khadija Lahlou-Laforet, Maryam Samadi, Valerie Krivosic, Thomas Blanc, Laurence Amar, Nelly Burnichon, Caroline Abadie, Stephane Richard, Anne-Paule Gimenez-Roqueplo

Summary: VHL disease is a common cancer predisposition syndrome, and adherence to surveillance for VHL pathogenic variant carriers in children is crucial for favorable clinical outcomes. A specific and adapted procedure for predictive genetic testing, followed by specialized follow-up within an expert network, leads to complete adherence to the surveillance protocol and positive medical interventions.

EUROPEAN JOURNAL OF HUMAN GENETICS (2022)

Review Oncology

Therapeutic significance of ARID1A mutation in bladder cancer

Marina Conde, Ian J. Frew

Summary: This review discusses the functions of ARID1A in bladder urothelial carcinoma and highlights its potential as a therapeutic target.

NEOPLASIA (2022)

Article Oncology

Percutaneous Thermal Ablation for Renal Tumors in Patients with Birt-Hogg-Dube Syndrome

Sylvain Bodard, Idris Boudhabhay, Charles Dariane, Christophe Delavaud, Sylvain Guinebert, Dominique Joly, Marc-Olivier Timsit, Arnaud Mejean, Virginie Verkarre, Olivier Helenon, Stephane Richard, Jean-Michel Correas

Summary: Percutaneous thermal ablation (TA) could be a safe and efficient nephron-sparing treatment for renal cell carcinoma (RCCs) associated with Birt-Hogg-Dube (BHD) syndrome. The indications for ablation depend on various factors, and the involvement of a tumor board is crucial. In this study, percutaneous TA was found to be a safe and efficient treatment option for BHD syndrome-related RCCs, even in patients with advanced chronic kidney disease.

CANCERS (2022)

Article Cell Biology

Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma

Daniel A. Mohl, Simon Lagies, Kyra Zodel, Matthias Zumkeller, Asin Peighambari, Athina Ganner, Dietmar A. Plattner, Elke Neumann-Haefelin, Mojca Adlesic, Ian J. Frew, Bernd Kammerer

Summary: Clear cell renal cell carcinoma (ccRCC) accounts for 75% of kidney cancers and is primarily caused by biallelic inactivation of the von Hippel-Lindau tumor suppressor gene (VHL). Cancer cells in ccRCC undergo metabolic reprogramming and excrete higher amounts of modified nucleosides, which cannot be recycled. Using a murine ccRCC model, researchers identified potential biomarkers for ccRCC, such as pseudouridine, 5-methylcytidine, and 2'-O-methylcytidine, and specific enzymes responsible for their formation. This study provides promising candidates for validation in clinical trials.

CELLS (2023)

Article Cell Biology

SCD5 Regulation by VHL Affects Cell Proliferation and Lipid Homeostasis in ccRCC

Athina Ganner, Antonia Philipp, Simon Lagies, Laura Wingendorf, Lu Wang, Felicitas Pilz, Thomas Welte, Kelli Grand, Soeren S. Lienkamp, Marinella Klein, Bernd Kammerer, Ian J. Frew, Gerd Walz, Elke Neumann-Haefelin

Summary: VHL inactivation is associated with the development of ccRCC, and VHL regulates SCD5 and fatty acid metabolism. SCD5 expression is regulated by VHL and HIF, and loss of SCD5 promotes cell proliferation and metabolic shift towards ceramide production.

CELLS (2023)

Article Genetics & Heredity

Update of the UMD-VHL database: classification of 164 challenging variants based on genotype-phenotype correlation among 605 entries

Gregory Mougel, Amira Mohamed, Nelly Burnichon, Sophie Giraud, Pascal Pigny, Brigitte Bressac-de Paillerets, Delphine Mirebeau-Prunier, Alexandre Buffet, Frederique Savagner, Pauline Romanet, Yannick Arlot, Betty Gardie, Anne-Paule Gimenez-Roqueplo, Christophe Beroud, Stephane Richard, Anne Barlier

Summary: The von Hippel-Lindau (VHL) disease is a hereditary tumour syndrome caused by germline mutations in the VHL tumour suppressor gene. Accurate classification of VHL variants is important for patient management and genetic counselling. In this study, 164 VHL variants were expertly classified, including missense variants, difficult interpretation variants, and their associated phenotypes. The experts modified the classification of 87 variants, including 30 variants of uncertain significance.

JOURNAL OF MEDICAL GENETICS (2023)

No Data Available